^
    Apply
    Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer (INX-315-01) (NCT05735080)
    Phase 1/2
    Incyclix Bio
    Recruiting
    Last update posted :
    05/22/2024
    Initiation :
    03/28/2023
    Primary completion :
    12/01/2025
    Completion :
    06/01/2026
    HER-2 • ER • CCNE1
    |
    HER-2 negative • CCNE1 amplification
    |
    INX-315